drugset / Trial / NCT06481202
A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers
RandomizedParallel-groupDouble-blindOther
Summary
This is a randomized double-blind comparative parallel group study of the safety, pharmacokinetics and pharmacodynamics of Complarate and Actemra® in healthy volunteers. Participants received a single intravenous dose of tocilizumab 8 mg/kg. The follow up period was 43 days
Timeline
- Start
- 2022-04-11
- Primary completion
- 2022-06-14
- Completion
- 2022-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Complarate® | Unknown | 8 mg/kg | Intravenous |
| Comparator | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
Indications
No indication recorded.